The GFPD is proud to be one of 126 organizations, representing or treating patients impacted by rare diseases and other acute or chronic health conditions, urging Congress to include a full five-year reauthorization of the programs listed in Section F, Title V of H.R. 6833 (‘Title V programs’), of the Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023 and to include important reforms to the Federal Food, Drug and Cosmetic Act (FFDCA) in any end-of-year legislative package under development. See the letter below from the GFPD and our partners.